Adenosine
Other Cardiac Preparations
Sold as Tissen NF 10 · by Selected Recovering… · PETITCOCHON TONE UP BODY…
- Drug class
- Other Cardiac Preparations
- Availability
- Prescription and OTC
- Routes
- Topical, Intravenous
- Markets covered
- 3
- Products on record
- 18
- FDA reports (12 mo)
- 107
Overview
Adenosine is an active pharmaceutical ingredient in the Other Cardiac Preparations group (C01EB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 11 | May 22, 2026 |
| US United States | FDA | 4 | November 25, 2024 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
GBUnited Kingdom· MHRA
11 products
Uses
Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory by-pass tracts (Wolff- Parkinson-White Syndrome). Paediatric population Rapid conversion to a normal sinus rhythm of paroxysmal supraventricular tachycardia in children aged 0 to 18 years.
Diagnostic Indications Aid to diagnosis of broad or narrow complex supraventricular tachycardias. Although adenosine injection will not convert atrial flutter, atrial fibrillation or ventricular tachycardia to sinus rhythm, the slowing of AV conduction helps diagnosis of atrial activity.
Sensitisation of intra-cavitary electrophysiological investigations.
How to take
USUnited States· FDA
4 products
Uses
Intravenous adenosine injection, USP is indicated for the following:
Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). , Valsalva maneuver), should be attempted prior to adenosine injection, USP administration.
It is important to be sure the adenosine injection, USP solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION). Adenosine injection, USP does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm.
In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine injection, USP administration.
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Adenosine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 265. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL298310457 · revised April 19, 2024
- [2]FDA DailyMed · 1809fc7e-f5d8-18… · revised May 9, 2024 [PDF]
- [3]Health Canada (DPD) · 02267659 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.